Our Alliance

Mission of the ILD Community Network

To unite, empower, and support individuals and organizations in advancing awareness, research, and care for those impacted by Interstitial Lung Disease.

Connect to ILD experts in your region

Partner with trusted ILD experts in your region to unlock your potential and achieve your goals.

ILD EXPERTS

Jeanette Hart

PA-C

Jeannette Hart is a board-certified physician assistant with over 13 years of experience specializing in rheumatology. She earned her Master of Clinical Health Services (MCHS) through the University of Washington’s MEDEX Physician Assistant Program in 2012. She began her career in private practice and successfully navigated transitions through both a hospital acquisition and a merger with a large healthcare system—all while refining her clinical expertise and leading efforts to improve patient access, operational efficiency, and best practices in rheumatology care. Committed to advancing healthcare delivery, Jeannette pursued a second master’s degree in Health Administration (MHA), further strengthening her leadership in clinical operations. She is now co-founder and co-owner of PNW Arthritis and Rheumatology, a private rheumatology practice opening October 1, 2025. Jeannette is passionate about education and mentorship, regularly precepting PA students and family medicine residents in her community. She is also the Pacific Northwest Director for RhAPP (Rheumatology Advanced Practice Providers) and has proudly served on its faculty since its inception.

Amanda Mixon

PA-C

Amanda Mixon, PA-C, is a physician assistant specializing in rheumatology at UCHealth's Rheumatology Clinic in Fort Collins, Colorado. With over 17 years of experience, she focuses on managing inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and connective tissue diseases like lupus. Amanda emphasizes a team-based approach to care, working closely with both patients and specialists to ensure timely and effective treatment plans. She is also a co-founder of the Rheumatology Advanced Practice Providers (RhAPP) group, where she contributes to educating and supporting colleagues in rheumatology. Amanda's dedication to patient care extends to fostering collaboration between rheumatology and dermatology, particularly in managing complex connective tissue diseases that involve both skin and joint manifestations

William Saalfeld

DNP

William Saalfeld is an Adult-Gerontology Acute Care Nurse Practitioner specializing in Rheumatology at the Arthritis Center of Nebraska, where he has practiced since 2017. He holds a Doctor of Nursing Practice from the University of Nebraska Medical Center. Before specializing in rheumatology, he gained experience as a registered nurse in critical care and palliative care. Saalfeld is a member of the Association of Rheumatology Health Professionals.

Candace Ryan

PA-C

Candace Ryan attended the University of Southern Mississippi where she earned a bachelor's degree in Biologic. After relocating to Arizona, she attended Midwestern University and received a master’s in physician assistant studies. She initially worked in Pediatrics and then transitioned to Rheumatology where she has been for the past 17 years at the Arizona Arthritis and Rheumatology Associates. Candace has been on faculty with RhAPP for the past 4 years. In her spare time, she enjoys spending time with her family, riding her bike, and playing with her dogs.

Shayla Sanders

FNP-BC

Shayla Sanders is a board-certified Family Nurse Practitioner with extensive experience in providing comprehensive care to patients with complex medical conditions. Passionate about patient education and evidence-based practice, Shayla focuses on empowering individuals through personalized care plans. With a strong background in [specific specialty or focus area, if known], she is dedicated to fostering collaborative patient-provider relationships to optimize health outcomes.

Heather Mambretti

PA-C

Heather Mambretti, PA-C, is a physician assistant specializing in rheumatology at Texas Rheumatology in League City, Texas. She has been practicing since 2011 and provides care for patients with autoimmune and musculoskeletal conditions. Heather is affiliated with Texas Rheumatology and works alongside other specialists to offer comprehensive treatment plans for her patients. She is dedicated to improving the health and well-being of individuals dealing with rheumatologic diseases​.

Heather Finlayson

PA-C

Heather Finlayson, MS, PA-C, is a certified Physician Assistant for Summit Rheumatology in Littleton, Colorado. She previously worked at National Jewish Health Rheumatology and started at Colorado Arthritis Associates in Rheumatology in 2012. She has also taught rheumatology courses at Rocky Vista University PA program since 2022. Heather is a member of the Association of Rheumatology Professionals (ARP) (division of American College of Rheumatology-ACR), and the Association of Women in Rheumatology (AWIR). She is currently the AWIR Denver Local Chapter Co-Lead, a Rheumatology Advanced Practice Providers (RhAPP) faculty member and has served on several ACR/ARP committees.

Shannon Ghizzoni

PA-C

Shannon Ghizzoni is a board-certified Physician Assistant specializing in rheumatology. With a passion for providing comprehensive care to patients with rheumatic conditions, Shannon focuses on patient education, disease management, and improving quality of life. She is dedicated to staying current with the latest advancements in rheumatology and fostering collaborative relationships with patients and healthcare teams to deliver personalized, evidence-based care.

Iris Zink

MSN, ANP, RN-BC

Iris Zink, MSN, ANP-BC, APRN, is a board-certified nurse practitioner specializing in rheumatology in East Lansing, Michigan. She co-founded Pine Hollow Partners, an Early Arthritis Intervention Clinic, in August 2016 to serve the underserved community. With over 24 years of experience, Iris is affiliated with McLaren Greater Lansing and Hayes Green Beach Memorial Hospital. She is dedicated to providing comprehensive care to patients with rheumatologic conditions, emphasizing early intervention to prevent deformity, disability, and death.

Naomi Amudala

RN, MSN

After graduating from MGH Institute of Health Professions in 2009 with a Master’s in Nursing, Naomi joined the division of Rheumatology at Boston University. Her primary focus was evaluating and managing patients with vasculitis as well as acting as co-investigator in multiple clinical trials in vasculitis. In 2018 she moved to Philadelphia and started working at Penn Medicine Rheumatology. The majority of her time continues to be dedicated to the clinical care of patients with vasculitis and other rare diseases as well as engaging in research. In 2022 Naomi joined the board of directors for RhAPP, which is a national organization for APPs and pharmacists in Rheumatology.

Kyle George

PA-C

Kyle George, PA-C, is a physician assistant with over 16 years of experience in rheumatology. He specializes in managing autoimmune diseases such as rheumatoid arthritis and osteoporosis. Kyle collaborates with a multidisciplinary team, providing personalized and comprehensive care to his patients.

Jessica Glennie

MSN, APRN

Jessica Glennie is a certified nurse practitioner who has worked in outpatient pulmonary medicine at the Cleveland Clinic in Cleveland, Ohio for 8 years. She manages patients in the interstitial lung disease program, including care of patients with idiopathic pulmonary fibrosis, autoimmune related interstitial lung disease, hypersensitivity pneumonitis, occupational lung diseases, and drug-induced interstitial lung disease. She is co-director of the Cleveland Clinic’s ILD multidisciplinary conference.

Jenny Williams

PA-C

Jenny Williams is Clinical Instructor of Medicine-Pulmonary Sciences & Critical Care at the University of Colorado Denver - Anschutz Medical Campus. She completed her medical training as a Physician Assistant at DeSales University. Since then, she has worked as a PA in General Pulmonary at St. Luke’s University Hospital in Pennsylvania, Lung Transplant and Cystic Fibrosis at Stanford University Hospital, and currently Interstitial Lung Disease and Lung Transplant at the University of Colorado.

Cori Fratelli

MSN, FNP-C

Cori Fratelli has a unique background in both basic science and clinical research, which has informed her interest in clinical medicine. Her past basic science research includes asthma, airway hyperresponsiveness, cystic fibrosis, and lung cancer. Her past clinical research includes COPD and interstitial lung disease (ILD). Presently, she is interested in how research translates into personalized medicine. Her clinical focus is mainly on ILD, but she also sees general pulmonary medicine patients, as needed.

Kelsey Cramer

MSN, AGACNP-BC, DNP

Kelsey Cramer is a board-certified adult-gerontology acute care nurse practitioner specializing in pulmonary medicine at Froedtert & the Medical College of Wisconsin. She focuses on interstitial lung disease (ILD), pulmonary hypertension (PH), and sarcoidosis. Kelsey earned her MSN and DNP from Rush University and is dedicated to delivering patient-centered care, education, and support for those managing complex lung conditions.

Kathy Lindell

PhD, RN, ATSF, FAAN

Kathleen Lindell is a nurse scientist and educator specializing in pulmonary fibrosis. She is an associate professor at the Medical University of South Carolina (MUSC) College of Nursing. Dr. Lindell is dedicated to advancing pulmonary care through research, education, and interdisciplinary collaboration, focusing on improving outcomes and quality of life for patients with pulmonary diseases.

Rebekah Edwards

DNP, FNP-C

Rebekah Edwards graduated with her NSM summa cum laude and earned her DNP from from the edson college of Nursing & Health Innovation. She currently works as a nurse practitioner in the advanced lung disease program at norton Thoracic Institute, Saint Joseph;s Hospital and Medical Center in Phoenix Arizona.

Felicia Mackey

MSN, FNP-BC, PCCN, CCRN

Felicia Mackey, MSN, FNP-BC, RN, PCCN, CCRN, is a board-certified Family Nurse Practitioner specializing in pulmonary and sleep medicine at Pulmonary Medicine Associates in Sacramento, California. She earned her Master of Science in Nursing with a Family Nurse Practitioner focus from Sonoma State University, following a Bachelor of Science in Nursing from California State University, Sacramento. Her foundational nursing education includes an Associate Degree in Nursing from Sacramento City College. Felicia holds multiple certifications, including Progressive Care Certified Nurse and Critical Care Registered Nurse, and is a member of the California Association of Nurse Practitioners and the American Association of Critical-Care Nurses. She is dedicated to partnering with patients to achieve their health goals, aiming for long, healthy, and happy lives.

Kelley Brant

NP

With over 17 years of diverse clinical experience, Kelley Brant is a dedicated healthcare professional with a passion for advancing pulmonary care. A graduate of San Diego State University with a BSN, Kelley began her career as a registered nurse in high-acuity settings, including the emergency room, ICU, and urgent care, where she honed her ability to excel in fast-paced, multidisciplinary environments. Kelley earned her MSN from the University of South Alabama and is double board-certified as a Family Nurse Practitioner and Emergency Nurse Practitioner. For the past 2.5 years, Kelley has served as a nurse practitioner specializing in pulmonary medicine, with a particular focus in interstitial lung disease (ILD). As an ILD program coordinator, Kelley has gained experience in managing complex patient populations and remains actively involved in general pulmonary care, including COPD, asthma, and other respiratory conditions. Kelley also has a strong interest in research, supporting her facility’s participation in several randomized controlled trials to advance evidence-based practice. Beyond clinical work, Kelley is committed to fostering connections within the healthcare community. As a member of AANP, CHEST, and Utah Nurse Practitioners, she emphasizes professional development and collaboration to improve patient outcomes and advance the field of pulmonary care.

Shannon Benesh

DNP, NP-C

Shannon Benesh, DNP, RN-BC, AGNP-C, is a Nurse Practitioner at Columbia University Irving Medical Center, specializing in Interstitial Lung Disease within the Division of Pulmonary and Critical Care. She earned her BSN from James Madison University and her MSN from Adelphi University, later completing her Doctor of Nursing Practice at Stony Brook University with a project focused on early advance care planning in ILD. Shannon has clinical experience as an RN at leading academic hospitals across various specialties and is certified as a Progressive Care Certified Nurse and Adult-Gerontology Nurse Practitioner. She is an active member of AANP, has contributed to published ILD research, and participates in national advisory boards dedicated to improving ILD care. She lives in Brooklyn with her husband and their dog and enjoys traveling, reading, running, and the occasional cocktail.

ILD Community Network Educational Events

CME EVENT

6th Annual RhAPP National Conference

September 25 @ 12:00 pm - September 27 @ 12:00 pm MST

Course Overview: Rheumatology Advanced Practice Providers (RhAPP) is an initiative dedicated to developing educational programs, providing professi..

Bridging Specialties: Tackling Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease

October 02 @ 06:00 pm - 08:00 pm CST

Register Today!..

CME EVENT

APAPP Regional Conference

September 30 @ 05:00 pm - 08:30 pm EST

Please register to join us at the Hilton Cleveland Downtown on September 30, 2025, at 5:00 PM EST for the APAPP Regional Meeting. ..

CME EVENT

APAPP Regional Conference

October 07 @ 05:00 pm - 08:30 pm MST

Please register to join us at the Hilton Garden Inn Denver/Cherry Creek on October 7, 2025, at 5:00 PM MST for the APAPP Regional Meeting.  ..

CME EVENT

RhAPP Regional Chapter Summit

October 16 @ 05:00 pm - 08:30 pm EDT

Register Now!..

Bridging Specialties: Tackling Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease

November 04 @ 06:00 pm - 08:00 pm EST

Register Today!..

CME EVENT

APAPP Regional Conference

October 14 @ 05:00 pm - 08:30 pm CST

Please register to join us at the Marriott Dallas Las Colinas on October 14, 2025, at 5:00 PM CST for the APAPP Regional Meeting.  ..

CME EVENT

APAPP Regional Conference

November 05 @ 05:00 pm - 08:30 pm EST

Details Coming Soon!..

CME EVENT

APAPP Regional Conference

November 12 @ 05:00 pm - 08:30 pm EST

Details Coming Soon!..

CME EVENT

APAPP Regional Conference

November 13 @ 05:00 pm - 08:30 pm PST

Register to join us in Los Angeles for the APAPP Regional Conference. More details coming soon!..

CME EVENT

RhAPP Regional Chapter Summit

November 15 @ 09:00 am - 12:30 pm EDT

Register Now!..

CME EVENT

RhAPP Regional Chapter Summit

December 06 @ 09:00 am - 12:30 pm EDT

Registration Details Coming Soon!..

CME EVENT

RhAPP Regional Chapter Summit

November 06 @ 05:00 pm - 08:30 pm CDT

Register Now!..

CME EVENT

RhAPP Regional Chapter Summit

January 16 @ 05:00 pm - 08:00 pm PST

Details Coming Soon!..

CME EVENT

RhAPP Regional Chapter Summit

October 30 @ 05:00 pm - 08:30 pm EST

Register Now!..

Bridging Specialties: Tackling Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease

November 06 @ 05:30 pm - 08:00 pm MST

Bridging Specialties: Tackling Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease

October 16 @ 06:00 pm - 08:30 pm MST

Bridging Specialties: Tackling Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease

October 23 @ 05:30 pm - 08:30 pm EST

Bridging Specialties: Tackling Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease

October 09 @ 06:00 pm - 08:30 pm EST

Bridging Specialties: Tackling Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease

November 25 @ 12:00 pm - 12:00 pm EST

ILD Digital Learning Center

Podcasts

Podcasts

Webcast

Webcast

Industry Resources

News

News

Association of Abatacept with Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease: An Emulated Target Trial

July 2025

CONCLUSION: Abatacept was associated with a lower risk of mortality compared with rituximab in patients with RA-ILD. Because clinicians may preferentially reserve abatacept for less aggressive RA-ILD, residual confounding by indication cannot be excluded; thus, the association should not be interpreted as proof of causality. Prospective randomized trials are needed to confirm whether abatacept confers a true survival advantage.

Classification and course of pulmonary hypertension associated with end-stage COPD

July 2025

CONCLUSION: Unbiased longitudinal invasive follow-up and assessment of lung volumes by plethysmography provided evidence of an association of lung volume and PVR.

High Prevalence of Abnormal Baseline Lung Function in Pediatric and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Report from the TRANSPIRE Study

July 2025

CONCLUSIONS: Pretransplant pulmonary dysfunction is common and predicts sustained posttransplant impairment and lower survival. Comprehensive baseline assessment may aid in risk stratification and guide early interventions to improve long-term respiratory outcomes in pediatric and young adult HSCT patients.

Lysophospholipid metabolism, clinical characteristics, and artificial intelligence-based quantitative assessments of chest CT in patients with stable COPD and healthy smokers

July 2025

The specific role of lysophospholipids (LysoPLs) in the pathogenesis of chronic obstructive pulmonary disease (COPD) is not yet fully understood. We determined serum LysoPLs in 20 patients with stable COPD and 20 healthy smokers using liquid chromatography-mass spectrometry (LC-MS) and matching with the lipidIMMS library, and integrated these data with spirometry, systemic inflammation markers, and quantitative chest CT generated by an automated 3D-U-Net artificial intelligence algorithm model....

Detection of structural pulmonary changes with real-time high-fidelity analysis of expiratory CO<sub>2</sub>

July 2025

There is an unmet need for breath-based markers for pulmonary vascular disease (PVD). We developed a fully-automatic algorithm to analyse expiratory CO2 flow from resting ventilation and evaluated the clinical associations of our readouts. &#xD;We enrolled patients with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), pulmonary arterial hypertension (PAH) and healthy controls and evaluated fractionated volumes for dead space, mixed space (MSV) and alveolar space,...

Anti-Inflammatory Versus Antifibrotic Therapies for the Management of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Protocol for a Systematic Review and Meta-Analysis

July 2025

CONCLUSIONS: This systematic review and meta-analysis will provide a comprehensive comparison of antifibrotic and anti-inflammatory therapies in the treatment of chronic RA-ILD. The findings will help inform clinical decision-making, support evidence-based treatment selection, and identify gaps in current research. By addressing both efficacy and safety, this review aims to guide future studies and improve patient outcomes for this complex and debilitating condition.

Treatment Strategies for Acute Exacerbation of Interstitial Lung Disease Associated with Systemic Autoimmune Rheumatic Diseases in Chinese Patients: A Scoping Review

July 2025

Connective tissue disease-related interstitial lung disease (CTD-ILD) refers to a range of pulmonary complications arising from connective tissue disorders, characterized by alveolar inflammation and interstitial fibrosis. Various factors, such as the specific type of connective tissue disease, infections, and hypoxemia, influence acute exacerbations of CTD-ILD. Treatment strategies typically include targeted interventions for precipitating factors, glucocorticoids, immunosuppressants, and...

Progressive Systemic Sclerosis-Associated Interstitial Lung Disease With Clinical-Radiographic Dissociation and Delayed Transplant Access: A Case Report

July 2025

Systemic sclerosis-associated interstitial lung disease (ILD) is a major contributor to morbidity and mortality in patients with diffuse systemic sclerosis. We present the case of a 47-year-old man with fibrotic non-specific interstitial pneumonia who experienced worsening hypoxemia and dyspnea following COVID-19, despite ongoing treatment with mycophenolate mofetil and prednisone. His oxygen requirement increased from 6-8 L/minute to 15 L/minute at rest, even as imaging showed stable fibrosis...

A potential new entity pending further validation of pulmonary primary interstitial Tumor: Lymphangioleiomyomatosis-like

July 2025

Primary pulmonary interstitial tumors represent a group of lung diseases. We encountered a case of a pulmonary primary interstitial tumor not previously reported in the literature. Based on existing research, this disease cannot be classified into any known subtype. We propose this disease as a potential new entity pending further validation-Pulmonary Primary Interstitial Tumor-Lymphangioleiomyomatosis-like (PIT-LAM). Histologically, this tumor is located within the interstitium, exhibiting...

Severe drug-induced interstitial lung disease after photoimmunotherapy with cetuximab-sarotalocan sodium in a patient with oropharyngeal cancer: A case report

July 2025

CONCLUSION: We report the first case of DIILD caused by CS-PIT. Because cetuximab is a component of CS, CS-PIT has the potential to induce DIILD. Risk assessments and monitoring for DIILD are recommended for patients receiving CS-PIT.

Diagnostic yield and safety of transbronchial lung cryobiopsy using 1.7-mm probes in interstitial lung disease

July 2025

CONCLUSIONS: The incorporation of TBLC pathological findings in the MDD improved diagnostic certainty and facilitated decisions regarding treatment strategies. TBLC using a 1.7-mm single-use probe with a freezing duration of 5 s can safely obtain sufficient tissue specimens for the diagnosis of ILD.

Efficacy and safety of anlotinib combined with immunotherapy as first-line treatment in elderly patients with advanced non-small cell lung cancer

July 2025

CONCLUSIONS: Our findings suggest that the combination of anlotinib and immunotherapy represents a promising first-line therapeutic approach for elderly patients with locally advanced NSCLC, characterized by meaningful clinical efficacy and an acceptable safety profile. Further investigation may be warranted to validate the long-term therapeutic value of this treatment regimen in the elderly population.

Involvement of miR-205-5p in mediating the development of nodular thyroid disease associated with coal worker's pneumoconiosis via pulmonary extracellular vesicles

July 2025

CONCLUSION: miR-205-5p in pulmonary extracellular vesicles mediates the development of nodular thyroid disease associated with coal worker's pneumoconiosis through the ATF4/CHOP signaling axis. Further research is essential to comprehensively investigate the specific targets through which miR-205-5p derived from pulmonary extracellular vesicles triggers the development of nodular thyroid disease associated with coal worker's pneumoconiosis via the ATF4/CHOP signaling axis.

Exploration of pharmacodynamic material basis and mechanism of Jinbei Oral Liquid against idiopathic pulmonary fibrosis based on UHPLC-Q-TOF-MS/MS and network pharmacology

July 2025

This study aims to explore the pharmacodynamic material basis of Jinbei Oral Liquid(JBOL) against idiopathic pulmonary fibrosis(IPF) based on serum pharmacochemistry and network pharmacology. The ultra-high performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry(UHPLC-Q-TOF-MS/MS) technology was employed to analyze and identify the components absorbed into rat blood after oral administration of JBOL. Combined with network pharmacology, the study explored the...

B cells and systemic sclerosis interstitial lung disease

July 2025

Interstitial lung disease is an important complication of systemic sclerosis (SSc-ILD) with high mortality and morbidity. Recent clinical studies in SSc-ILD have led to FDA-approved therapies in SSc-ILD. Importantly, evidence from these studies has been extrapolated to guide management of interstitial lung diseases of other systemic autoimmune rheumatic diseases. Pathogenesis of SSc-ILD involves interplay between fibroblasts and the innate and adaptive immune system. A central role for the B...

Circulating extracellular vesicles as predictive biomarkers of progressive interstitial lung disease in systemic sclerosis-a prospective cohort study

May 2025

CONCLUSION: Circulating EV levels are increased in SSc and correlate with ILD. In particular, ICAM1 + EVs may be a novel biomarker of PF-ILD, identifying SSc patients at high risk of progression who may require early aggressive treatment. Based on our results, the role of EVs in the pathogenesis and progression of ILD should be investigated further.

The Role of Anti-MDA5 Antibodies in Rapidly Progressive Interstitial Lung Disease: A Case Report and Literature Review

May 2025

CONCLUSION: This case underscores the need for increased awareness of this condition among clinicians to improve early diagnosis and treatment outcomes.

The Spectrum of Epidermolysis Bullosa in KwaZulu-Natal, South Africa

May 2025

CONCLUSION: JEB, with a recurrent pathogenic variant in LAMB3, emerged as the predominant subtype among African Zulu patients, underscoring the critical need for early diagnosis and tailored management strategies in resource-limited settings. Integrating clinicopathological and genetic data is essential for accurate diagnosis and prognosis, emphasizing the importance of advanced diagnostic tools in improving outcomes for EB patients in South Africa.

The Role of Bronchoscopy in the Diagnosis of Interstitial Lung Disease: A State-of-the-Art Review

May 2025

The diagnostic evaluation of interstitial lung diseases (ILDs) remains challenging due to their heterogeneous etiologies and overlapping clinical and radiographic patterns. A confident diagnosis often necessitates histopathological sampling, particularly when high-resolution computed tomography and serologic assessments are inconclusive. While surgical lung biopsy (SLB) has long been considered the diagnostic gold standard, its invasiveness, associated morbidity, and limited feasibility in...

Potential Utility of Combined Presepsin and LDH Tracking for Predicting Therapeutic Efficacy of Steroid Pulse Therapy in Acute Exacerbation of Interstitial Lung Diseases: A Pilot Study

May 2025

Background/Objectives: The usefulness of presepsin, which is released from macrophages, in acute exacerbation of interstitial lung diseases (AE-ILDs) is unknown. We aimed to investigate the utility of monitoring presepsin with other AE-ILD markers before and after steroid pulse therapy in AE-ILDs. Methods: This pilot single-center retrospective observational study involved 16 patients with AE-ILDs, including the AE of idiopathic pulmonary fibrosis and idiopathic nonspecific interstitial...